In a patient with well-controlled ulcerative colitis on tofacitinib for several years, would you consider switching to upadacitinib for a more favorable side effect profile?

We usually do not change away from a medication to which the patient is having a sustained response without AE. Upadacitinib is a selective Jak but same class as tofacitinib and it is unclear how much if any of a difference there is between the two in terms of AE.

If it aint broke, dont fix it! No difference in AE profiles between tofa and upa.